首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Ureido-modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in vitro evaluation
【24h】

Ureido-modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in vitro evaluation

机译:ureido改性的羧甲基壳聚糖 - 移植物 - 硬脂酸聚合物纳米胶束作为幽门螺杆菌的甲状腺霉素的靶向递送载体:制备和体外评估

获取原文
获取原文并翻译 | 示例
           

摘要

The effect of antibiotics in the stomach for curing Helicobacter pylori infection is hampered by the adverse gastric environment and low bioavailability of the administered drugs. Concerning these challenges, a polymeric nano micelle was developed. Initially, carboxymethyl chitosan (CMCS) was hydrophobically modified with stearic acid (SA), and the obtained CMCS-g-SA co-polymers was further conjugated with urea to acquire U-CMCS-g-SA co-polymers. Sphere-shaped nano-micelles (UCS-NMs) with the particle sizes of approximately 200 nm were obtained with the U-CMCS-g-SA co-polymers. It was specified that this nano-micelle had no cell toxicity to AGS cells, and it could maintain a stable particle size for 6 h in simulated gastric fluid and for 24 h in 1 x PBS. Attractively, the CMCS backbones granted this nano-micelle an excellent retention time in the stomach, almost 24 h; meanwhile, the grafted ureido groups conferred effective targeting to H. pylori. This nano-micelle could load clarithromycin with high efficiency and exhibited slow release of this antibiotic in a slightly alkaline environment. In vitro inhibitory assay also indicated that a significantly enhanced anti-H. pylori activity was achieved by using this nano-micelle. This work demonstrated that the U-CMCS-g-SA nano-micelle is a proper carrier for targeted delivery of clarithromycin to H. pylori under the gastric mucus layer. (C) 2019 Elsevier B.V. All rights reserved.
机译:抗生素在胃中用于固化幽门螺杆菌感染的效果是由施用的药物的不利胃环境和生物利用度低而受到阻碍。关于这些挑战,聚合物纳米胶束的开发。最初,羧甲基壳聚糖(CMCS)中的溶液疏水用硬脂酸(SA)改性,将得到的CMCS-G-SA共聚物,具有脲进一步缀合于获得的U CMCS-G-SA共聚物。球形纳米胶束(UCS-NMS)具有约200纳米的颗粒尺寸与U CMCS-G-SA共聚物获得。它指定了一个这种纳米胶束没有细胞毒性AGS细胞,并且它可以在模拟胃液保持稳定的颗粒大小6小时,并在1×PBS 24小时。好看,CMCS骨架授予此纳米胶束优异的保留时间在胃中,几乎24小时;同时,接枝脲基赋予有效靶向幽门螺杆菌。这种纳米胶束可以加载克拉霉素具有高效率和这种抗生素表现出缓慢释放在微碱性的环境。在体外抑制测定法还表明,一个显著增强的抗-H。幽门螺旋杆菌活性,通过使用这种纳米胶束实现。这项工作表明,在U-CMCS-G-SA纳米胶束是用于胃粘液层下的克拉霉素的靶向递送到幽门螺旋杆菌的适当的载体。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号